Elucidating the precise pharmacological mechanism of action (MOA) of naturally developing compounds may be hard. Although Tarselli et al. (60) designed the 1st de novo artificial pathway to conolidine and showcased that this naturally occurring compound correctly suppresses responses to each chemically induced and inflammation-derived pain, the pha